FATORES INFLUENTES NA SATISFAÇÃO DO CONSUMIDOR NO SETOR SUPERMERCADISTA: UMA ANÁLISE DO CONTRASTE DA PENALIDADE E RECOMPENSA

O setor de varejo supermercadista está inserido em um ambiente altamente competitivo, devido ao aumento da concorrência e ao crescimento na diversidade dos produtos e serviços ofertados aos clientes. Para obter sucesso nesse mercado, as organizações necessitam compreender os aspectos que influenciam na satisfação dos seus consumidores. Esta pesquisa tem por objetivo analisar os fatores influentes na satisfação do consumidor no setor supermercadista, por meio de uma análise do contraste da penalidade e recompensa (Penalty and Reward Contrast analysis - PRC). Por meio de uma pesquisa quali-quanti, foram analisados 25 atributos relacionados à satisfação dos consumidores, com uma amostra de 660 respondentes de uma rede de supermercados. Dentre os principais resultados, demonstra-se que as dimensões de Ambiente e Produto obtiveram penalidade e recompensa, o Tempo obteve penalidade, enquanto o Atendimento obteve Recompensa, em relação ao desempenho. A dimensão de segurança não obteve impacto significativo no desempenho do supermercado.

Synthesis and Biological Evaluation of a γ-Cyclodextrin-based Formulation of the Anticancer Agent 5,6,11,12,17,18,23,24-Octahydrocyclododeca[1,2-b:4,5-b’:7,8-b’’:10,11-b’’’]tetraindole (CTet)

none10sìopenLucarini, Simone; DE SANTI, Mauro; Antonietti, Francesca; Brandi, Giorgio; Diamantini, Giuseppe; Fraternale, Alessandra; Paoletti, MARIA FILOMENA; Tontini, Andrea; Magnani, Mauro; Duranti, AndreaLucarini, Simone; DE SANTI, Mauro; Antonietti, Francesca; Brandi, Giorgio; Diamantini, Giuseppe; Fraternale, Alessandra; Paoletti, MARIA FILOMENA; Tontini, Andrea; Magnani, Mauro; Duranti, Andre

Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a complex, immune-mediated, disorder which leads to several gastrointestinal and systemic manifestations determining a poor quality of life, disability, and other negative health outcomes. Our knowledge of this condition has greatly improved over the last few decades, and a comprehensive management should take into account both biological (i.e., disease-related, patient-related) and non-biological (i.e., socioeconomic, cultural, environmental, behavioral) factors which contribute to the disease phenotype. From this point of view, the so called 4P medicine framework, including personalization, prediction, prevention, and participation could be useful for tailoring ad hoc interventions in IBD patients. In this review, we discuss the cutting-edge issues regarding personalization in special settings (i.e., pregnancy, oncology, infectious diseases), patient participation (i.e., how to communicate, disability, tackling stigma and resilience, quality of care), disease prediction (i.e., faecal markers, response to treatments), and prevention (i.e., dysplasia through endoscopy, infections through vaccinations, and post-surgical recurrence). Finally, we provide an outlook discussing the unmet needs for implementing this conceptual framework in clinical practice

pretreatment with the monoacylglycerol lipase inhibitor urb602 protects from the long term consequences of neonatal hypoxic ischemic brain injury in rats

Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of neonatal hypoxic–ischemic brain injury in rat

An endocannabinoid mechanism for stress-induced analgesia

Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stress-induced analgesia, is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB(1) receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol (2-AG) and anandamide. A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase, selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB1-dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase, which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target